Literature DB >> 15626586

Multiple P450 substrates in a single run: rapid and comprehensive in vitro interaction assay.

Miia Turpeinen1, Jouko Uusitalo, Uusitalo Jouko, Jorma Jalonen, Jalonen Jorma, Olavi Pelkonen, Pelkeonen Olavi.   

Abstract

The dramatically increased number of new chemical entities (NCE) used in drug discovery has raised a demand for efficient and rapid drug metabolism screening techniques. The aim of this study was to develop a global in vitro metabolic interaction screening test utilising the N-in-1 approach. A cocktail consisting of 10 CYP-selective probes with known kinetic, metabolic and interaction properties in vivo was incubated in a pool of human liver microsomes, and metabolites of melatonin (CYP1A2), coumarin (CYP2A6), bupropion (CYP2B6), amodiaquine (CYP2C8), tolbutamide (CYP2C9), omeprazole (CYP2C19 and CYP3A4), dextromethorphan (CYP2D6), chlorzoxazone (CYP2E1), midazolam (CYP3A4) and testosterone (CYP3A4) were analysed simultaneously using LC/TOF-MS. Performance of the method was assessed with cDNA expressed P450s and diagnostic CYP-specific inhibitors. The results were in good accordance with literature and our previous studies. The cocktail developed is suitable for fast and reliable in vitro screening of the interaction potential and characteristics of NCEs.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15626586     DOI: 10.1016/j.ejps.2004.10.006

Source DB:  PubMed          Journal:  Eur J Pharm Sci        ISSN: 0928-0987            Impact factor:   4.384


  22 in total

1.  High-Throughput Cytochrome P450 Cocktail Inhibition Assay for Assessing Drug-Drug and Drug-Botanical Interactions.

Authors:  Guannan Li; Ke Huang; Dejan Nikolic; Richard B van Breemen
Journal:  Drug Metab Dispos       Date:  2015-08-18       Impact factor: 3.922

2.  Metabolic and efflux properties of Caco-2 cells stably transfected with nuclear receptors.

Authors:  Timo Korjamo; Jukka Mönkkönen; Jouko Uusitalo; Miia Turpeinen; Olavi Pelkonen; Paavo Honkakoski
Journal:  Pharm Res       Date:  2006-08-09       Impact factor: 4.200

3.  Cytochrome P450 3A Enzymes Catalyze the O6-Demethylation of Thebaine, a Key Step in Endogenous Mammalian Morphine Biosynthesis.

Authors:  Valerie M Kramlinger; Mónica Alvarado Rojas; Tatsuyuki Kanamori; F Peter Guengerich
Journal:  J Biol Chem       Date:  2015-07-08       Impact factor: 5.157

4.  Effect of nicotine on cytochrome P450 1A2 activity.

Authors:  Janne Hukkanen; Peyton Jacob; Margaret Peng; Delia Dempsey; Neal L Benowitz
Journal:  Br J Clin Pharmacol       Date:  2011-11       Impact factor: 4.335

5.  Novel cyclic phosphate prodrug approach for cytochrome P450-activated drugs containing an alcohol functionality.

Authors:  Kristiina M Huttunen; Niina Mähönen; Jukka Leppänen; Jouko Vepsäläinen; Risto O Juvonen; Hannu Raunio; Hanna Kumpulainen; Tomi Järvinen; Jarkko Rautio
Journal:  Pharm Res       Date:  2007-02-15       Impact factor: 4.200

6.  Effects of nicotine on cytochrome P450 2A6 and 2E1 activities.

Authors:  Janne Hukkanen; Peyton Jacob Iii; Margaret Peng; Delia Dempsey; Neal L Benowitz
Journal:  Br J Clin Pharmacol       Date:  2010-02       Impact factor: 4.335

Review 7.  CYP2B6: new insights into a historically overlooked cytochrome P450 isozyme.

Authors:  Hongbing Wang; Leslie M Tompkins
Journal:  Curr Drug Metab       Date:  2008-09       Impact factor: 3.731

8.  High-throughput fluorescence assay of cytochrome P450 3A4.

Authors:  Qian Cheng; F Peter Guengerich
Journal:  Methods Mol Biol       Date:  2013

9.  Biotransformation and pharmacokinetics of the novel anticancer drug, SYUIQ-5, in the rat.

Authors:  Qi-Biao Su; Fan He; Xue-Ding Wang; Su Guan; Zhi-Yong Xie; Lai-You Wang; Yu-Jing Lu; Lian-Quan Gu; Zhi-Shu Huang; Xiao Chen; Min Huang; Shu-Feng Zhou
Journal:  Invest New Drugs       Date:  2007-10-06       Impact factor: 3.850

10.  Effects of the CYP3A5 genotype on omeprazole sulfoxidation in CYP2C19 PMs.

Authors:  Katsuyoshi Sugimoto; Tsukasa Uno; Tomonori Tateishi
Journal:  Eur J Clin Pharmacol       Date:  2008-06       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.